Telomir-1 reverses STAT1 epigenetic silencing in prostate cancer, outperforming Paclitaxel and Rapamycin

Telomir Pharmaceuticals, Inc.

In PC3 xenograft model, Telomir-1 fully reversed STAT1 hypermethylation after 21-day oral daily dosing.
No STAT1 reversal was seen with Paclitaxel; only partial demethylation was observed with Rapamycin.
Telomir-1 also reduced TMS1 hypermethylation, a pro-apoptotic tumor suppressor involved in immune signaling.
Telomere length in tumor tissue was not elongated, addressing a key safety concern for telomere-targeting compounds.
Company is advancing Telomir-1 toward IND filing and evaluating it in Wilson's disease, AMD, autism, and dysphonia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.